Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

Polypeptides

Linaclotide 851199-59-2

Linaclotide 851199-59-2

98% up, Medical Grade
  • Product Details

Product Information


Product name

Linaclotide

CAS No.

851199-59-2

Molecular Formula

C59H79N15O21S6

Molecular Weight

1526.736 g/mol

Quality Standard

98% up, Medicine Grade

Appearance

White powder

Sequence

H-Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH cyclic(1-6),(2-10),(5-13)-tris(disulfide)


COA of Linaclotide


Test

Specifications

Appearance

White or almost white crystalline powder

Identity by HPLC

The reaction is same with the reference substance

Amino Acid Composition

±20% of theoretical

Purity (HPLC)

≥ 98.0%

Related Substance(By HPLC)

Total Impurities(%)≤ 2.0%
Largest Single Impurity(%)≤ 1.0%

Acetate Content(By HPLC)

≤15%

Water Content(By HPLC)

≤5.0%

Bacterial Endotoxins

≤5IU/mg


Usage

Function of Linaclotide


Linaclotide can bind to the guanylate cyclase C-type receptor (GC-C) in the intestinal tract after being taken orally into the human body to increase the intracellular and extracellular cyclic guanylic acid (cGMP) concentration and stimulate the secretion of intestinal juice , To accelerate the migration of the gastrointestinal tract, thereby increasing the frequency of bowel movements. Due to its unique mechanism of action, it is promising to become a therapeutic drug that can not only treat constipation, but also treat abdominal distension, abdominal pain and other clinical symptoms.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

LIRAGLUTIDE
Liraglutide 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
nonapeptide-1
Nonapeptide-1 158563-45-2
99% up by HPLC
Biotinoyl Tripeptide
Biotinoyl Tripeptide-1 299157-54-3
98% up by HPLC, Cosmetic Grade
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact